Even though the clinical trial did not meet it's primary end point, the results are very encouraging for APOE4 carriers:

Main results:

• 52% benefit on ADAS-cog, maintaining above baseline for 52 weeks (p=0.04)

• 102% benefit on CDR-SB, remaining at baseline for 78 weeks

• Zero ARIA-E or ARIA-H across all patients

• Hippocampal volume protection (p=0.04) correlating with clinical benefit (r=0.89)

Brain preservation

• Preservation of brain volume, a decrease in atrophy

• Protection across all brain regions

• Strong correlation between brain preservation and cognitive benefit

• Some patients showed brain volume increase (neurogenesis?)

And here's the kicker: it's just a pill.

• 265mg twice a day.

• No monthly infusions.

• No MRI monitoring every 3 months.

• No crazy side effects like ARIA

• No $56,000 annual cost.

The drug works by preventing oligomers (those invisible toxic proteins that are 10x worse than the plaques we see on scans) from ever forming.

What was also very interesting for me:
Patients with the Arctic mutation have full Alzheimer's with completely CLEAN brain scans.
Their brains are being destroyed by these oligomers we can't even see.
This drug stops that process.

Here's a blog post about Homotaurine a potential short term solution while we wait for Valiltramiprosate https://blog.thephoenix.community/p/alz-801-trial-results

If you are interested to run an experiment with Homotaurine, I have created a post in our Experiment space in the Phoenix Community.

If you are not in, here’s the best time to join us before we move away from the Founding Member period (= lifetime access instead of monthly subscription).
Apply to join the Phoenix Community here.

Cheers,

Kevin